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The T3G mutation at nucleotide 705 in the second
intron of the b-globin gene creates an aberrant 5* splice
site and activates a 3* cryptic splice site upstream from
the mutation. As a result, the IVS2-705 pre-mRNA is
spliced via the aberrant splice sites leading to a defi-
ciency of b-globin mRNA and protein and to the genetic
blood disorder thalassemia. We have shown previously
that in cell culture models of thalassemia, aberrant
splicing of b-thalassemic IVS2-705 pre-mRNA was per-
manently corrected by a modified murine U7 snRNA
that incorporated sequences antisense to the splice sites
activated by the mutation. To explore the possibility of
using other snRNAs as vectors for antisense sequences,
U1 snRNA was modified in a similar manner. Replace-
ment of the U1 9-nucleotide 5* splice site recognition
sequence with nucleotides complementary to the aber-
rant 5* splice site failed to correct splicing of IVS2-705
pre-mRNA. In contrast, U1 snRNA targeted to the cryp-
tic 3* splice site was effective. A hybrid with a modified
U7 snRNA gene under the control of the U1 promoter
and terminator sequences resulted in the highest levels
of correction (up to 70%) in transiently and stably trans-
fected target cells.
The use of antisense oligonucleotides for down-regulation of
gene expression is well documented. The oligonucleotides are
most frequently targeted to mRNA where they block transla-
tion or lead to degradation of the message by RNaseH (1).
Alternatively, to inhibit transcription, oligonucleotides are de-
signed to form triplex structures with the sequences in pro-
moter regions of DNA. Both strategies result in down-regula-
tion of the targeted genes and may be useful in the treatment
of cancer (2–4), viral infections (5–7), and other diseases
(8–11).
A variety of antisense RNAs were also used for down-regu-
lation of gene expression. They were especially effective when
the antisense function of the targeting RNA was combined with
ribozyme activity (12–14). In another approach, antisense
RNAs were designed as an external guide sequence that acti-
vated endogenous RNaseP, resulting in degradation of the tar-
geted message (15–17). To promote stability, the antisense
constructs were usually embedded within larger stable RNA
molecules such as mRNAs, tRNAs, and small nuclear RNAs
(snRNAs)1 (18–22). This combination not only stabilized the
RNAs but also directed them either to the cytoplasm (mRNA
and tRNA) or to the nuclei (snRNAs).
Work in this laboratory showed that in addition to down-
regulation of target genes, antisense oligonucleotides could
restore the activity of genes inactivated by mutations that
affect splicing of pre-mRNA and result in genetic disorders.
Restoration of gene activity was accomplished by targeting the
splice sites created or activated by several mutations in thalas-
semia (23–26), cystic fibrosis (27), and in a mouse mdx model of
Duchenne muscular dystrophy (28). Thus, modification of splic-
ing by treatment with antisense oligonucleotides provides a
potential alternative to gene therapy protocols involving the
replacement of defective genes.
Treatment of patients with genetic diseases with antisense
oligonucleotides, which do not remove the mutation but rather
repair the defective pre-mRNA, would require lifelong periodic
administrations. This drawback would be alleviated if the pa-
tients were subjected to treatment with vectors stably express-
ing the appropriate antisense RNAs. Under these conditions
the effects of RNAs should result in long term, if not perma-
nent, restoration of gene expression.
A group of snRNAs, U snRNAs, which in cells form ribonu-
cleoprotein particles (snRNPS) and are involved in numerous
RNA processing reactions (29–31), appear particularly attrac-
tive as carriers for antisense sequences effecting correction of
splicing. They are localized in the nucleus (the site of splicing),
are stable, are expressed at relatively high levels, and most
importantly, interact with their natural RNA targets by base
pairing via complementary, i.e. antisense nucleotides. Indeed,
we have shown previously that stable expression of U7 snR-
NAs, which are normally involved in the processing of the
39-ends of histone pre-mRNAs (32–35), but which were modi-
fied to target splice sites in the human b-globin gene, led to
permanent restoration of correct splicing of thalassemic b-glo-
bin pre-mRNA (19). In this report we have investigated
whether U1 snRNA may be used as an effective modifier of
splicing.
The design of U1 snRNA as an antisense agent for modifica-
tion of splicing was based on several considerations. There are
approximately 1 3 106 copies of U1 per cell as compared with
5 3 103 copies of U7 snRNA molecules (29). Because there are
30 functional U1 genes (36) and only one U7 gene (37, 38), the
expression of U1 snRNA per gene copy is still approximately
6-fold higher than that of U7, making U1 potentially a more
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periments reported here show that U1 snRNA targeted to the
39- but not the 59-splice site could be used for antisense repair
of aberrantly spliced thalassemic human b-globin pre-mRNA.
EXPERIMENTAL PROCEDURES
Cell Lines—The HeLa cell line carrying the thalassemic IVS2-705
human b-globin gene (39) and the cell lines stably expressing the
modified U7 snRNAs (19) were grown in minimum essential medium
modified for suspension cells (S-MEM), 5% fetal calf sera, 5% horse
sera, 50 mg/ml gentamicin, and 200 mg/ml kanamycin. Cotransfection of
the HeLa IVS2-705 cells with a plasmid carrying a hygromycin-resist-
ance gene and a U1.U7.324 snRNA expressing plasmid (see below and
Fig. 5A) in the presence of LipofectAMINE (8 mg/ml, Life Technologies,
Inc., as recommended by the manufacturer), was used to generate the
stable cell line. Stable transfectants were isolated after selection in
media containing 250 mg/ml hygromycin.
U1 snRNA Constructs—The wild type U1 plasmid (U1.wt) was a kind
gift from Dr. W. Marzluff (University of North Carolina). It contains the
mouse U1 snRNA gene, U1 promoter, and 39 sequences. In the U1.309,
U1.318, and U1.324 constructs, the natural 9 nucleotide sequence (nt.
3–11) complementary to pre-mRNA 59 splice sites was replaced with a
9-, 18-, or 24-nucleotide sequence complementary to the cryptic 39 splice
site activated by the IVS2-705 mutation. In the U1.Beta and U1.524
construct, the same 9-nucleotide sequence (nt. 3–11) was replaced with
168 nucleotides from the second intron (IVS2-549-717) or 24 nucleotides
complementary to the 59 splice site, respectively. In the U1.U7.324
construct, nearly the entire U1 gene (nt. 3–161) was replaced with the
U7.324 gene, whereas the U1 promoter and 39 sequences were retained.
Polymerase chain reaction (PCR)-based mutagenesis methods were
used in all the above constructions (40, 41). Refer to (19) for U7.324
construction.
Transient Expression of Modified U1 and U7 snRNAs—For all ex-
periments, HeLa IVS2-705 cells were plated 24 h before treatment in
24-well plates at 105 cells per 2-cm2 well. All HeLa cell lines were grown
in S-MEM, 5% fetal calf sera, 5% horse sera, 50 mg/ml gentamicin, and
200 mg/ml kanamycin. The cells were treated for 10 h with the modified
snRNA plasmids (indicated in the figure legends) complexed with 8
mg/ml LipofectAMINE or 8 mg/ml DMRIE-C (Life Technologies, Inc.).
Unless otherwise indicated, the RNA was isolated 24-h post-transfec-
tion. Note that the variability of efficiency of transfection between
experiments may be responsible for the differences in the effects of
U7.324 seen in Figs. 2B, 3, 4A, and 6A. This variability is much less
pronounced within a single experiment, and therefore the comparisons
of the efficiency of correction within an experiment are more accurate.
RT-PCR Analysis—Total RNA was isolated using TRI-Reagent
(MRC, Cincinnati, OH). RNA (200 ng) was analyzed by reverse tran-
scription-PCR (RT-PCR) using rTth DNA polymerase as recommended
by the manufacturer (PerkinElmer Life Sciences). To maintain the
linear concentration-dependent response, PCR was carried out for 18
cycles (42) with the addition of 0.2 mCi of [a-32P]dATP to the PCR
reaction mixture. Correction of human b-globin pre-mRNA was de-
tected with forward and reverse primers spanning positions 21–43 of
exon 2 and positions 6–28 of exon 3, respectively, in b-globin mRNA.
RT-PCR products were separated on 8% non-denaturing polyacryl-
amide gels. The gels were dried and autoradiographed with Kodak
BioMax film.
RNase Protection Assay—The assay was performed using the RPA II
Ribonuclease Protection Assay Kit (Ambion Inc., Austin, TX) with
probes antisense to the regions containing the U1.324, U1.524, or
U1.U7.324 snRNA genes. The probes included 258 nucleotides comple-
mentary to the U1.324 or U1.524 plasmids and 145 nucleotides from the
U1.U7.324 plasmid. Probes generated from U1.524 and U1.324 (mouse
U1a) hybridize with endogenous human U1 snRNA (U1a) with 1-base
pair mismatch resulting in a 152-base pair band after RNase digestion.
U1.524 and U1.324 snRNAs are detected as 176-base pair bands. The
digestion of the U1.U7.324 (mouse U7) probe generates a 62-nucleotide
U7-protected band; this probe does not hybridize with endogenous
human U7 snRNA.
Following transient transfection, 1 mg of total cellular RNA or 1 mg of
tRNA was hybridized at 44 °C overnight with 0.5 ml of radiolabeled
probe in the hybridization buffer. Following RNase treatment, samples
were separated on 5% non-denaturing polyacrylamide gels. The gels
were dried and autoradiographed with Kodak BioMax film.
Protein Analysis—Transfected cells were treated with hemin (10 mM,
Fluka, Switzerland) in serum free medium for 4 h immediately preced-
ing the isolation of protein. Blots of proteins separated on a 10%
Tricine-SDS-polyacrylamide gel (43) were incubated with polyclonal
affinity purified chicken anti-human hemoglobin IgG as primary anti-
body and rabbit anti-chicken horseradish peroxidase-conjugated IgG as
secondary antibody (Accurate Chemicals, Westbury, NY). The blots
were developed with an ECL detection system (Amersham Pharmacia
Biotech).
Image Processing—All autoradiograms were captured by a Dage-
MTI CCD72 video camera (Michigan City, IN), and the images were
processed using NIH IMAGE 1.61. NIH IMAGE was also used for
quantification of the autoradiograms. Correctly spliced b-globin mRNA
was quantified by densitometry of the autoradiograms, and the results
were expressed as the percentage of correct product relative to the sum
of the correct and aberrant products. The results were corrected to
account for the 2-fold higher [32P]dAMP content of the PCR product
derived from aberrantly spliced mRNA than that from correctly spliced
mRNA.
RESULTS
U1.324 snRNA Targeted to the Aberrant 39 Splice Site in
IVS2-705 pre-mRNA—A T3G mutation at nucleotide 705 of
intron 2 in human b-globin pre-mRNA (IVS2-705) generates an
aberrant donor (59) splice site and activates a cryptic acceptor
(39) splice site 126 nucleotides upstream from the mutation. As
a result, IVS2-705 pre-mRNA is spliced incorrectly, and the
b-globin mRNA retains a fragment of the intron (Fig. 1A). This
fragment prevents proper translation of b-globin leading to
reduced levels of hemoglobin and to b-thalassemia (44).
Success in utilizing modified U7 constructs that had the 18
nucleotide anti-histone pre-mRNA sequence replaced with the
anti-IVS2-705 sequence, as well as contained a modified Sm
sequence (SmOPT), prompted the modification of U1 snRNA as
an antisense carrier. To block aberrant splicing and induce
correct splicing of the IVS2-705 b-globin pre-mRNA, a series of
modified U1 snRNAs, containing sequences antisense to the
aberrant 39 splice site were generated (Fig. 1B). The length of
the antisense sequences in the constructs ranged from 9 to 168
nucleotides.
Transfection of HeLa cells stably expressing IVS-705 b-glo-
bin pre-mRNA with U1.309 resulted in barely detectable cor-
rection of b-globin splicing (Fig. 2A, lane 2). In the U1.309
construct, the 9 nucleotides, which in native U1 snRNA are
antisense to the 59 splice site, were replaced with nucleotides
complementary to the cryptic 39 splice site in the b-globin
FIG. 1. A, correction of aberrant splicing of IVS2-705 pre-mRNA by
modified U1snRNA. Box, exons; line, introns. The dotted lines represent
correct and aberrant splicing pathways. Modified U1 snRNA (heavy
bar) is targeted to the cryptic 39 splice site. B, structure of U1 snRNA
constructs. Wild-type U1 snRNA includes two stem loops, the Sm se-
quence (open box) and a sequence antisense to the 59 splice sites of
pre-mRNA (shaded box). In anti-705 U1 snRNAs, this sequence is
replaced with antisense sequences to the aberrant 39 or 59 splice sites in
the b-globin gene. The U1 promoter and 39-end forming regions flank
the gene.
Restoration of Correct b-Globin Splicing by Modified U1 snRNAs 35915
intron. This modification does not change the overall length of
U1 snRNA and therefore should not destabilize it. Thus, the
negative result suggests that the antisense sequence was not
able to compete with the splicing factors that assembled at the
39 splice site during aberrant splicing of IVS2-705 pre-mRNA.
This assumption was further supported by the findings that
the levels of splicing correction by U1.318 and U1.324, contain-
ing, respectively, 18 and 24 nucleotide antisense sequences
(Fig. 2A, lanes 3 and 4) were increased in a manner commen-
surate with the length of the inserted sequence. Further elon-
gation of the antisense sequence to 168 nucleotides (U1.Beta,
Fig. 2A, lane 5), abolished rather than enhanced correction of
splicing. The b antisense sequence, which extends through the
putative branch points and the aberrant 39and 59 splice sites in
the IVS2-705 b-globin intron, was expected to interfere with
aberrant splicing on the basis of its effect when placed in the
modified U7 gene (U7.Beta, Fig. 2B, lane 3). Unlike in U1
snRNA, the U7.Beta and U7.324 corrected splicing to a similar
degree (Fig. 2B, lanes 2 and 3). This suggests that the long
antisense sequence affects the structure, stability, and/or in-
teraction of the U1 and U7 particles with the target sequences
in a very different manner.
We have compared in more detail the ability of the two
similar U7 and U1 snRNAs, i.e. those with 24 nucleotide anti-
sense sequences, U7.324 and U1.324, to correct IVS2-705
pre-mRNA splicing. For both snRNAs, transient transfection of
IVS2-705 HeLa cells resulted in dose-dependent correction of
splicing (Fig. 3, lanes 6–11). Quantitation of the results by
densitometry (see “Experimental Procedures”) showed that at 1
mg of DNA plasmids per 105 cells, the level of correction was as
high as 56 and 70% for the U1.324 and U7.324 constructs,
respectively. The effect of U1.324 was dependent on the anti-
sense sequence because the transfection of the cells with a
plasmid expressing wild-type U1 snRNA did not restore correct
splicing of b2globin IVS2-705 pre-mRNA (Fig. 3, lanes 3–5).
U1.524 snRNA Targeted to the Aberrant 59 Splice Site—The
fact that transfection with U1.324 and U7.324 plasmids led to
efficient correction of splicing of IVS2-705 pre-mRNA indicated
that the 24-nucleotide antisense sequence did not destabilize
the snRNPs, and that it bound to the 39 splice site strongly
enough to inhibit aberrant splicing. Because modified U7.524
snRNA targeted to the aberrant IVS2-705 59 splice site was
effective in correction of splicing (Fig. 4A, lane 3), it seemed
possible that U1.524 might be similarly effective. However, as
shown in Fig. 4A, lane 5, U1.524 did not correct b-globin splic-
ing; other constructs, U1.324, U7.524, and U7.324, were active
as expected (Fig. 4A, lanes 2–4).
To confirm that the inability of the U1.524 construct to
correct splicing was not because of lack of its expression, an
RNase protection assay was performed (Fig. 4B). Densitometry
analysis of the autoradiogram indicated that both U1.324 and
U1.524 were expressed in transient transfections at compara-
ble levels (Fig. 4B, lanes 3 and 6). Comparison of the intensity
of the bands representing anti-thalassemic and endogenous U1
snRNAs (176 and 152 nucleotides, respectively) indicated that
these RNAs were expressed at, approximately, a 1:5 ratio.
Thus, assuming that the wild-type U1 snRNA is present at 106
copies per cell (29), the amount of modified U1.324 and U1.524
was estimated to equal 2–3 3 105 copies per cell.
U7.324 snRNA Expressed from the U1 Promoter—In an at-
tempt to further improve the effectiveness of snRNA-based
vectors, we combined the strong U1 promoter and terminator
sequences with the coding sequence of the modified U7.324
gene. In transient transfections with 1 mg of plasmid, this
construct (U1.U7.324, Fig. 5A) was effective, resulting in ap-
proximately 70% correction of b-globin splicing (Fig. 5B, lane
2), whereas the U7.324 gene controlled by the U7 promoter
(Fig. 5B, lane 3) corrected splicing to approximately 60%. This
small increase in correction efficiency was consistent with the
higher level of U1.U7.324 expression over that of the U7.324
construct (Fig. 5C, lanes 3 and 4).
The effectiveness of the U7.324 and U1.U7.324 constructs
was compared in a time-course experiment in transiently
transfected cells. For both constructs, correctly spliced b2glo-
bin mRNA became detectable 12-h post-transfection (Fig. 6A,
FIG. 2. Effect of the length of antisense sequences in U1.3
snRNA on correction of IVS2-705 pre-mRNA splicing. A, RT-PCR
assay of total cellular RNA from IVS2-705 HeLa cells transfected with
U1 constructs. Lane 1, mock transfection. Lanes 2–4, U1.309, U1.318,
and U1.324 snRNAs directed against the 39 cryptic splice site with
respectively, a 9-, 18-, or 24-nucleotide antisense sequence. Lane 5,
U1.Beta, with a 168-nucleotide antisense sequence spanning two puta-
tive branch sites, the 39 cryptic splice site and the aberrant 59 splice site.
Lane 6, RNA from human blood (Hb). B, effect of antisense length in
modified U7 snRNAs on correction of IVS2-705 pre-mRNA splicing.
Lane 1, mock transfection; lane 2, U7.324, with a 24-nucleotide se-
quence antisense to the 39 cryptic splice site; lane 3, U7.Beta; lane 4,
RNA from human blood (Hb). The sizes (in nucleotides) of PCR bands
representing aberrantly and correctly spliced mRNAs are indicated on
the right. The same designations are used in RT-PCR assays shown in
Figs. 3, 4, 5, and 6. Quantitation of these results took into account the
approximately 2-fold higher [32P]dAp content of the aberrant PCR prod-
uct than that of the correct one.
FIG. 3. Correction of aberrant splicing by U1.324 and U7.324
snRNA. IVS2-705 cells transiently transfected with 0.25, 0.5, and 1 mg
of U1 or U7 snRNA constructs (top). Lane 1, RNA from human blood
(Hb); lane 2, mock transfection; lanes 3–5, cells transfected with wild
type U1 snRNA gene (U1.WT); lanes 6–8, and 9–11, cells transfected
with U1.324 and U7.324 constructs, respectively. All other designations
are as described in the legend to Fig. 2.
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lanes 4 and 5), and its level increased in a time-dependent
fashion at the 24- and 48-h time points (Fig. 6A, lanes 6–9).
There was no further increase 72-h post-transfection (Fig. 6A,
lanes 10–11). At every time point, the level of correction ef-
fected by U1.U7.324 snRNA was higher than that by U7.324
snRNA. The average of the results from this figure and Fig. 5
indicates that the U1.U7.324 construct is approximately 30%
more effective in splicing correction than its U7-only counterpart.
The RNase protection assay shows that the time course of
splicing correction is consistent with the levels of expression of
the two constructs (Fig. 6B). The U7.324 snRNA is not yet
generated 6-h post-transfection but is clearly detectable at
12–72-h time points, and its levels are higher upon transcrip-
tion from the U1 promoter (Fig. 6B, lanes 5, 7, 9 and 11 versus
lanes 6, 8, 10, and 12, respectively). Interestingly, translation
of b2globin protein was delayed relative to transcription and
splicing because it was not detectable for 24-h post-transfection
(Fig. 6C, lanes 2–5); b2globin was translated 24 h later (Fig.
6C, lanes 6–9). However, although an increasing time-depend-
ent correction of splicing is confirmed by the Western blot, a
quantitative difference between the U7 and U1.U7 constructs
is not evident. This may be because of low sensitivity of the
Western blot or loading error. Note that this error is elimi-
nated in RT-PCR assays by comparing the ratio of the spliced
products.
Because the main advantage of vector-transcribed antisense
RNA over synthetic antisense oligonucleotides is the possibility
of stable intracellular expression, a U1.U7.324-expressing
IVS2-705 HeLa cell line was generated. As expected, correct
splicing of IVS2-705 pre-mRNA was restored very efficiently
(77%) and persisted at this level throughout the time of culture
(Fig. 7). The growth rate of the cell line was comparable with
that of the wild-type HeLa cells (data not shown), suggesting
that the modified U7 snRNA is not toxic to the cells.
DISCUSSION
Approximately 15% of all point mutations that cause genetic
diseases affect splicing of pre-mRNA (45). Moreover, a great
majority of genes in higher eukaryotes are transcribed into
pre-mRNAs that undergo alternative splicing (46–49). Thus,
manipulation of splicing with antisense oligonucleotides and
RNAs offers a promising method of modification or repair of
spliced mRNAs. On the other hand, splice sites and other
sequences involved in pre-mRNA splicing appear to be unlikely
targets for the antisense approach because they interact with
numerous protein splicing factors and several snRNP particles
within the spliceosome (31, 50). Nevertheless, work from this
laboratory showed that blocking of aberrant splice sites by
antisense agents leads to restoration of correct splicing in
pre-mRNAs for b-globin, cystic fibrosis transmembrane con-
ductance receptor (CFTR) and dystrophin genes in systems
modeling thalassemia, cystic fibrosis, and Duchenne muscular
dystrophy, respectively (19, 23, 27, 28, 39). Previous work
showed that antisense oligonucleotides targeted to splice site
junctions in immediate early genes led to inhibition of replica-
tion of herpes simplex virus (52–54). Recently it has been found
that modification of alternative splicing of bcl-x pre-mRNA by
antisense oligonucleotides sensitized the cells to apoptotic
stimuli (55).2 Clearly, splice sites are accessible to antisense
agents, most likely because the spliceosome is formed de novo
for every splicing event and its interaction with pre-mRNA is
very dynamic (31).
Our previous work showed that the accessibility of the aber-
rant 39 splice site in IVS2-705 pre-mRNA to oligonucleotides
2 D. R. Mercatante and R. Kole, manuscript in preparation.
FIG. 4. RNase protection assay of U1 snRNA expression. A,
correction of aberrant splicing. Lane 1, mock transfection; lanes 2 and 3,
cells transfected with 1 mg of U7.324 and U7.524, respectively; lanes 4
and 5, cells transfected with 1 mg of U1.324 and U1.524, respectively. B,
RNase protection assay using RNAs from A. Lanes 1 and 4, tRNA (t)
mixed with probe; lanes 2 and 5, RNA from mock transfected cells
mixed with probe (M); lane 3, cells transfected with U1.324; lane 6, cells
transfected with U1.524. Bands from modified U1 (U1.mod, 176 nucle-
otides) and wild-type U1 (U1.wt, 152 nucleotides) are indicated. In lanes
1-3 and 4–6, the probes were transcribed from U1.324 and U1.524
plasmids, respectively, as described under “Experimental Procedures.”
FIG. 5. A, structure of U1.U7.324 snRNA construct. U7.324 snRNA
includes a stem loop structure, the SmOPT sequence, and a 24-nucle-
otide sequence antisense to the 39 cryptic splice and is flanked by the U1
promoter and terminator. B, correction of aberrant splicing by
U1.U7.324 snRNA. IVS2-705 cells were mock transfected (lane 1) or
transfected with 1 mg of U1.U7.324 (lane 2) and U7.324 (lane 3) plasmid
DNA. C, RNase protection assay. Lane 1, tRNA; lanes 2–4 RNAs from
B mixed with probe. Bands from modified U7 (62 nucleotides) and
undigested probe (145 nucleotides) are indicated.
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was ;8 times lower than that of the 59 splice site (26). The
difference in the accessibilities of the 39 and 59 aberrant splice
sites in IVS2-705 pre-mRNA to modified U7 snRNPs, particles
much larger than the oligonucleotides (Ref. 19 and Fig. 4A,
lanes 2 and 3), was not as pronounced. This difference may be
because of the fact that the modified U7 snRNP particle, car-
rying the appropriate Sm proteins, may mimic other snRNPs in
the spliceosome assembling on the splice sites. However, be-
cause of inappropriate antisense sequences and/or inappropri-
ate structure of modified U7, the spliceosome is dysfunctional,
resulting in inhibition of aberrant splicing.
In view of the observations regarding U7 snRNA it was
surprising that the modified U1 snRNA, U1.524, targeted to
the aberrant 59 splice site, was unable to inhibit aberrant
splicing. Lack of expression or instability of U1.524 was ex-
cluded by the RNase protection assay, which confirmed that
the inactive U1.524, and the active U1.324 were produced at
similar levels. One possibility is that U1.524 could not compete
with wild type U1 for binding to the 59 splice site because it was
expressed at one-fifth of the level of endogenous U1. Because
endogenous U1 does not initially interact with the 39 splice site,
it would not compete with U1.324 for binding to its target.
U1.524 ineffectiveness in inhibiting splicing may also be
because of the fact that, despite its modification, the construct
is still able to support the proper spliceosome assembly at the
59 splice site. This hypothesis is supported by several reports,
which have shown that modified U1 could, albeit inefficiently,
restore splicing at defective splice sites or redirect splicing to
sequences adjacent to canonical splice sites (56, 57). Of partic-
ular interest is the observation that U1 snRNA-targeted 14
nucleotides downstream from the 59 splice site still promoted
correct splicing presumably by forming the so-called commit-
ment complex, which then evolved into a functional spliceo-
some (56, 58). This interpretation is consistent with the fact the
U7 snRNAs targeted to the 39 and 59 splice sites were both
effective in splicing correction (Fig. 4A, lanes 2 and 3 and Ref.
19) even though their level of expression is likely to be lower
than that of U1 snRNA (59).
Several reports showed that modified U1 snRNA could be
used for down-regulation of targeted mRNAs (14, 18, 60–62).
They were particularly effective in inhibiting HIV replication
when a hammerhead ribozyme sequence was incorporated into
the U1 snRNA molecule (14, 60, 61). It is notable however, that
the most effective constructs were targeted either to the coding
sequences or to regions that included the 39 splice site se-
quences (14). Recently, an effective anti-HIV U1-ribozyme tar-
geted to the 59 splice site of REV pre-mRNA was constructed. In
this construct, the antisense/ribozyme sequence was located
within the body of the U1 molecule whereas the regular 59
antisense sequence was retained. Thus, the resulting RNA
bound simultaneously to the 59 splice site and to the adjacent
sequences, forming a double-target antisense molecule (14).
Interestingly, double-target U7 snRNAs were also found to be
more effective than the single target ones in correction of splic-
ing of several thalassemic b-globin pre-mRNAs (44). It appears
that the arrangement of closely spaced antisense sequences
may loop out and deform the targeted pre-mRNA, preventing
the formation of the spliceosome and inhibiting aberrant
splicing.
Because U6 snRNA has been used as an antisense vector by
several groups (20, 63–65) and because it differs from U7 and
U1 snRNA in important aspects of metabolism and structure
(29), we built a series of U6 constructs carrying either 24 or 168
nucleotide sequences antisense to the aberrant splice sites of
FIG. 6. Time course of splicing correction by U1.U7.324 snRNA
in transiently transfected cells. A, RT-PCR. Total RNA from cells
transfected with U7.324 (lanes 2, 4, 6, 8, and 10) and U1.U7.324 (lanes
3, 5, 7, 9, and 11) constructs was isolated at 6-, 12-, 24-, 48-, and 72-h
post-transfection (top). Lane 1, untreated cells; lane 12, human blood
(Hb). Percent correction at every time point is shown below the panel. B,
expression of U7 snRNA. The RNA from transfected cells was analyzed
by RNase protection assay. Lane 1, tRNA; lane 2, RNA from untreated
cells; lanes 3–12, the same RNA samples as analyzed in A, lanes 2–11,
respectively. C, immunoblot. Total protein from transfected cells was
isolated 12-, 24-, 48-, and 72-h post-transfection as indicated in lanes
2–9. Lane 10, human b2globin as size marker.
FIG. 7. Stable correction of IVS2-705 pre-mRNA splicing in cell
line 705U1.U7.324.F. Lane 1, RNA from IVS2-705 cell line; lane 2,
RNA from cell line 705U1.U7.324F; lane 3, RNA from human blood
(Hb).
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IVS2-705 pre-mRNA. Surprisingly, when transfected into
HeLa IVS2-705 cells, all of the constructs failed to correct
splicing of IVS2-705 pre-mRNA (data not shown). Notably, in
previous work, the effective U6 constructs were not targeted to
splice sites. It therefore seems plausible that in our system U6
was not able to compete with the splicing factors for splice site
targets. This could be because of the fact that U6 snRNA is
incorporated into snRNP particles only in conjunction with U4
snRNA (66–67 and 51), and in its absence U6 snRNA may be
unable to access the splice site.
The combination of the promoter and termination sequences
from the U1 gene with the modified U7 snRNA sequence in-
creased expression of U7 snRNA and concomitant correction of
b2globin pre-mRNA splicing, providing an improvement over
the U7.324 vector. Thus, the ability to modify splicing by two
types of snRNA molecules, U1 and U7, generated from three
different vectors U1, U7 and U1.U7 broadens the possibilities
of using the antisense approach as a form of gene therapy and
may offer certain advantages in different cell types or tissues.
The obvious next step for this work is to deliver the antisense
U1 or U7 constructs in vectors that are stably expressed in
stem cells and/or erythroid progenitor cells. If efficient correc-
tion of splicing by antisense RNAs were achieved in these cells
in a thalassemic patient, a more balanced synthesis of a- and
b-globin would have been restored and the clinical symptoms of
thalassemia ameliorated. Note that the correction would have
occurred in the b-globin pre-mRNA, which was properly tran-
scribed from the gene that remained in its natural chromo-
somal environment. In consequence, the possibility of overex-
pression or inappropriate expression of b-globin mRNA, an
important consideration in treatment of hemoglobinopathies,
would have been precluded. One concludes that repair of de-
fective pre-mRNAs by antisense agents offers an attractive
alternative to gene replacement therapy.
Acknowledgment—We thank Elizabeth Smith for excellent technical
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